NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

mRNA疫苗的全球市場

mRNA Vaccines

出版商 Global Industry Analysts, Inc. 商品編碼 994936
出版日期 內容資訊 英文 125 Pages
商品交期: 最快1-2個工作天內
價格
mRNA疫苗的全球市場 mRNA Vaccines
出版日期: 2021年05月01日內容資訊: 英文 125 Pages
簡介

全球mRNA疫苗的市場規模,預計在分析期間(2020年∼2027年)將以-0.7%的年複合成長率增長,從2020年的319億美元,到2027年達到305億美元。

本報告所分析的市場區隔之一的COVID-19疫苗部門,在分析期間中預計將以-5.9%的年複合成長率增長,達到222億美元。

本報告提供全球mRNA疫苗市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Arcturus Therapeutics, Inc.
  • Argos Therapeutics, Inc.
  • BioNTech SE
  • CureVac AG
  • eTheRNA
  • ethris GmbH
  • GlaxoSmithKline PLC
  • Moderna Therapeutics Inc.
  • Pfizer Inc.
  • Sangamo Therapeutics Inc.
  • Translate Bio Inc.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • 競爭的市場佔有率:各市場區隔
    • 癌症治療的標準化(類型)2020年和2027年的全球其他競爭對手市場佔有率地位
    • 主要參與者的感染疾病治療(類型)市場佔有率的明細:2020年和2027年
    • 預防感染(類型)其他競爭對手收益佔有率(%):2020年及2027年
    • 個別化癌症治療(類型)各企業的市場佔有率變化:2020年和2027年
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:42公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP23108

Abstract:

Global mRNA Vaccines Market to Reach $127.3 Billion by 2027

Amid the COVID-19 crisis, the global market for mRNA Vaccines estimated at US$64.9 Billion in the year 2021, is projected to reach a revised size of US$127.3 Billion by 2027, growing at a CAGR of 11.9% over the analysis period 2021-2027. COVID-19 Vaccine by Indication, one of the segments analyzed in the report, is forecast to reach US$119 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the cancer vaccine segment is readjusted to a revised 116.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $29.9 Billion, While China is Forecast to Grow at 17.2% CAGR

mRNA Vaccines market in the U.S. is estimated at US$29.9 Billion in the year 2021. China is forecast to reach a projected market size of US$13.2 Billion by the year 2027 trailing a CAGR of 17.2% over the analysis period 2021 to 2027. Among the other noteworthy geographic markets are Canada, Japan and Europe, each forecast to grow at 11.2% 10% and 10.6% respectively over the 2021-2027 period.

Select Competitors (Total 92 Featured) -

  • Arcturus Therapeutics, Inc.
  • Argos Therapeutics, Inc.
  • BioNTech SE
  • CureVac AG
  • eTheRNA
  • ethris GmbH
  • GlaxoSmithKline PLC
  • Moderna Therapeutics Inc.
  • Pfizer Inc.
  • Sangamo Therapeutics Inc.
  • Translate Bio Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • The Race Between the Virus & Vaccines Intensifies. Amidst this Chaotic Battle, Where Is The World Economy Headed in 2021?
    • Increased Hospital Admissions and Deaths Characterize Second and Third Wave
    • EXHIBIT 1: Daily New Confirmed Cases (Per Million) by Select Country
    • With IMF's Upward Revision of Global GDP Forecasts for 2021, Most Companies Are Bullish about a Global Economic Comeback.
    • EXHIBIT 2: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • Unprecedented Crisis Prompts Biden Administration to Support Efforts to Waive Intellectual Property Rights for COVID-19 Vaccines
    • EU Joins US in Quest to Waive COVID-19 Vaccine Patent Protections
    • mRNA - A CONCEPTUAL UNDERSTANDING
    • mRNA: A New Approach to Medicine
    • Long Wait & Scientific Breakthroughs
    • mRNA Vaccines - An Introduction
    • mRNA Vaccine Approvals
    • A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
    • Traditional Vs. mRNA Vaccines: Key Differences
    • Traditional Vs. mRNA Vaccines: The Development Process
    • How mRNA Vaccine Works & Earlier Testing Efforts
    • mRNA Vaccines: Safety Quotient
    • Other Notable Efforts Centered on mRNA Technology
    • Overcoming Challenges
    • As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community
  • GLOBAL MARKET OVERVIEW
    • Global mRNA Platform Market Set for a Stupendous Growth in Future
    • Riding COVID-19 Wave, mRNA Vaccines Take Center Stage & See Exciting Times Ahead
    • COVID-19 mRNA Vaccine Approval Details
    • COVID-19 Funding Details of Moderna,Pfizer, and CureVac Vaccine
    • EXHIBIT 3: Production Capacity of mRNA Frontrunners in Millions of Doses for 2021
    • COVID-19 Pandemic: An Eventful Year for RNA
    • EXHIBIT 4: COVID-19 Cases Worldwide by Country: As on May 17, 2021
    • COVID-19's Impact on Vaccine Development - A Transformative Shift to mRNA vaccines
    • mRNA Based Vaccines in Clinical Development
    • EXHIBIT 5: Vaccines in Human Trials by Technology
    • EXHIBIT 6: Vaccine Technologies in Pre-Clinical Studies
    • Battling the COVID-19 Pandemic: The Global Fight Extends Longer as Variants Emerge Stronger
    • COVID-19 Virus Can Adapt & Undergo 'Escape Mutation' to Pose Vaccine Challenge
    • Indian Variant of COVID-19 Virus Puts Healthcare System on Brink of Major Collapse
    • Investigating the Virulence Profile of India's N440K Variant
    • Is South African Variant a Formidable Threat?
    • E484K Mutation Challenges Vaccine Developers
    • Rising Cases in South Africa & Other Countries
    • California Strain Emerges to be More Contagious and Deadly
    • Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
    • Pfizer/BioNTech Trailing a Third Covid-19 Shot to Provide Variant Protection
    • Moderna's Variant-Specific Vaccine Candidate Ready for Clinical Study
    • mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market
    • The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market
    • Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations
    • The East Falls behind the West in Embracing the Revolutionary mRNA Technology for Developing Vaccines to Fight against COVID-19
    • RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE
    • Pfizer and BioNTech's COVID-19 Vaccine Receives World's First Authorization
    • UK Clinches the First Position in the World to Approve Pfizer's Vaccine
    • After UK, US Gives Nod to Pfizer's Vaccine
    • EU Approves Pfizer's Vaccine
    • BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
    • Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production
    • FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
    • Moderna's mRNA Vaccine Bags Approval from US FDA
    • Moderna Kick-Starts Inoculation in the US
    • FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
    • Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
    • Recent Market Activity
  • COMPETITIVE SCENARIO
    • BioNTech - A Pioneer in mRNA-based Vaccines and Therapies
    • List of BioNTech's mRNA Candidates in Clinical Trials for Cancer
    • Moderna's Ambitious Stride into Vaccine Development: From a Novice to Know All
    • Moderna's mRNA Prophylactic Vaccines
    • mRNA Cancer Vaccines
    • mRNA Intratumoral Immuno-Oncology
    • mRNA Systemic Secreted & Cell Surface Therapeutics
    • mRNA Systemic Intracellular Therapeutics
    • Sanofi Commences Clinical Trials of mRNA vaccine for Covid-19
    • mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon
    • Noteworthy Startups Exploiting mRNA Technology
    • Providence Therapeutics
    • pHion Therapeutics
    • eTheRNA immunotherapies & 20Med Therapeutics
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Coronavirus Cases Drive the Market Demand
    • Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead
    • mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum
    • EXHIBIT 7: Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
    • EXHIBIT 8: Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2018
    • EXHIBIT 9: Number of AIDS-Related Deaths (in Thousands) by Region for 2018
    • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
    • EXHIBIT 10: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • EXHIBIT 11: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Increasing Healthcare Expenditure to Foster Market Growth
    • EXHIBIT 12: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • EXHIBIT 13: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
    • EXHIBIT 14: Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
    • Regulatory Landscape for mRNA Vaccines
    • Regulatory Pathway Dealing with mRNA Vaccines
    • mRNA Vaccine Patent Scenario
    • The Best Route of Administration for mRNA Vaccines
    • CDC Study on Vaccine Effectiveness States mRNA Vaccines Offer More Protective Benefits than other Vaccines (March, 2021)
    • mRNA CANCER VACCINES
    • Introduction
    • Cancer Vaccines Vs. Immunotherapies
    • Clinical Trials of mRNA Encoding Immunostimulants
    • mRNA Vaccines Vs. DNA Vaccines
    • Clinical Trials of mRNA Encoding TAAs
    • mRNA Vaccines Vs. Other Vaccines
    • Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag)
    • mRNA Benefits Profile
    • mRNA Vaccines for Covid-19 Pave the Way
    • Challenges
    • Personalized mRNA Vaccine
    • Clinical Overview of mRNA Cancer Vaccines
    • mRNA encoding Immunostimulants
    • mRNA vaccine encoding tumor-associated antigens
    • mRNA vaccine encoding Neoantigen, personalized vaccine
  • MRNA INFLUENZA VACCINES
    • Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform
    • Vaccines Built on mRNA
    • Clinical Trials for mRNA Vaccines
    • mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts
    • mRNA: A Next-Generation Vaccination Approach
    • Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses
    • COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots
    • mRNA Vaccines Vs. Other Flu Shots
    • mRNA Technology, H/N Spike Proteins & Clinical Trials
    • mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines
    • Benefits & Limitations of mRNA Vaccines over Traditional Options
    • Benefits
    • Limitations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for mRNA Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
    • TABLE 2: World 6-Year Perspective for mRNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
    • TABLE 3: World Current & Future Analysis for COVID-19 mRNA Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
    • TABLE 4: World 6-Year Perspective for Covid-19 mRNA Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 5: World Current & Future Analysis for mRNA Cancer Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
    • TABLE 6: World 6-Year Perspective for mRNA Cancer Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 7: World Current & Future Analysis for Other mRNA Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
    • TABLE 8: World 6-Year Perspective for Other mRNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • US FDA Gives Nod to Pfizer and Moderna's mRNA Vaccines
    • Moderna to Supply 100 Million more Doses of COVID-19 Vaccine to the US Government
    • Lonza Announces Plans to Double Moderna COVID-19 Vaccine Output in Switzerland
    • US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for Ages 12 to 15
    • Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines for Global Supply
    • Market Analytics
    • TABLE 9: USA Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 10: USA 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • CANADA
    • Vaccination Gathers Steam Across Canada
    • EXHIBIT 15: Percentage (%) of Population Vaccinated (at least one dose) in Canada by Province/Territory As of May 3, 2021
    • COVID-19 Vaccine Deals in Canada
    • Pfizer Plans to Ramp up COVID-19 Vaccine Supply to Canada from May, 2021
    • Canada Grants Approval to Pfizer's COVID-19 Shot for Use in Children in 12-15 Years Age Group
    • Market Analytics
    • TABLE 11: Canada Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 12: Canada 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • JAPAN
    • COVID-19 Vaccination Programs in Japan Move Forward at Snail's Pace
    • Reasons Responsible for Setback
    • Vaccine Timeline & Availability
    • Japan Demands for Vaccine-Related Data
    • People's Low Trust in Vaccines
    • Japan's Efforts to Develop Indigenous Vaccines
    • Japan to Step Up COVID-19 Immunization Drive to Cover Geriatric Population
    • Japan Inks Deal with Pfizer to Secure 50 Million Additional Doses of COVID-19 Vaccine
    • Japan Pushes Shipments of Pfizer's COVID-19 Shots to Vaccinate Elderly
    • Market Analytics
    • TABLE 13: Japan Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 14: Japan 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • CHINA
    • BioNTech's Shot to Become First Western COVID-19 Vaccine to Secure Authorization in China
    • Market Analytics
    • TABLE 15: China Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 16: China 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • EUROPE
    • EU Urges Nations to Focus on COVID-19 Vaccine Sharing & Export to Beat the Pandemic (May, 2021)
    • COVID-19 Vaccine Drive Gathers Pace in Europe after Initial Glitch
    • EU Approves Pfizer's Vaccine
    • EU Eyes on Milestone Deal to Get 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
    • European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines
    • BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
    • Market Analytics
    • TABLE 17: Europe Current & Future Analysis for mRNA Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
    • TABLE 18: Europe 6-Year Perspective for mRNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027
    • TABLE 19: Europe Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 20: Europe 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • FRANCE
    • TABLE 21: France Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 22: France 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • GERMANY
    • TABLE 23: Germany Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 24: Germany 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • ITALY
    • Italy Plans to Produce mRNA Vaccines Domestically
    • Market Analytics
    • TABLE 25: Italy Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 26: Italy 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • UNITED KINGDOM
    • Market Analysis
    • UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine
    • Moderna Modifies Supply Contract with UK to Deliver Additional Doses of COVID-19 Vaccine
    • UK's Independent Vaccine Deals
    • Market Analytics
    • TABLE 27: UK Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 28: UK 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • REST OF EUROPE
    • TABLE 29: Rest of Europe Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 30: Rest of Europe 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • ASIA-PACIFIC
  • INDIA
    • Pfizer Looks Forward to Make its COVID-19 Vaccine Available in India
  • AUSTRALIA
    • Australia to Buy 20 Million Extra Doses of Pfizer COVID-19 Vaccine, Pivoting away from AstraZeneca
  • NEW ZEALAND
    • New Zealand Acquires Ultra-Cold Freezers to Store Pfizer's COVID-19 Vaccine
    • Market Analytics
    • TABLE 31: Asia-Pacific Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 32: Asia-Pacific 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027
  • REST OF WORLD
  • THE MIDDLE EAST
  • BAHRAIN
    • Bahrain Becomes the Second Country to Offer Emergency Use Approval to Pfizer's Vaccine
  • AFRICA
  • SOUTH AFRICA
    • New Virus Variant in South Africa Creates a Challenge
    • Highly Infectious COVID-19 Variant Spurs Countries to Impose Travel Ban from South Africa
  • LATIN AMERICA
    • Mass COVID-19 Vaccination Campaigns Launched in Latin American Countries
  • BRAZIL
    • Brazil Signs Deal to Buy Additional 100 Million Doses from Pfizer/BioNTech
  • MEXICO
    • Mexico's Cofepris Approves Emergency Use of Pfizer's COVID-19 Vaccine
    • Market Analytics
    • TABLE 33: Rest of World Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
    • TABLE 34: Rest of World 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 92